Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 60429-349

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 60429-349). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60429 349 60lb Levetiracetam 500mg Er Tabs

This is a description of a medication called Levetiracetam, manufactured by Apotex Inc. The medication is available in tablet form, with each tablet containing 500mg of Levetiracetam. The medication is packaged and distributed by GSMS Incorporated. Dosage information is available in the package insert, and it is essential to keep the medication out of reach of children. It is recommended to store the medicine at 20° to 25°C (68° to 77°F) and protect it from moisture. The medication guide should accompany each patient receiving the medication, and it should be dispensed in a tight, light-resistant container.*

FDA Label Image

60429 350 60lb Levetiracetam 750 mg Er Tabs

This is a bottle of release tablets that contains 60 tablets. The tablets contain 750mg of levetiracetam. The package comes with dosage information. It should be stored at a temperature of 20°C to 25°C, with permitted excursions to 15°C to 30°C (room temperature). Pharmacists are required to give each patient a medication guide, and dispensing comes in a tight, light-resistant container. It must be kept out of reach of children and protected from moisture. The tablets were manufactured by Apotex Inc, in Toronto, and packaged by GSMS, Inc. There is also some illegible text, which could not be evaluated.*

FDA Label Image

Fig1.jpg (Fig1)

The text describes the results of a study on the efficacy of Levetiracetam tablets in treating a medical condition. The study involved three groups of participants, with one group receiving a placebo and the other two groups receiving 1000 mg/day and 3000 mg/day of Levetiracetam tablets, respectively. The percentages given may represent different outcomes of the study, but without context, it is difficult to interpret them. The text also indicates that there were statistically significant differences between the Levetiracetam groups and the placebo group, meaning that the medication did have a measurable effect on the condition being studied.*

FDA Label Image

Fig2.jpg (Fig2)

FDA Label Image

Fig3.jpg (Fig3)

The text appears to be a table/chart with percentages and numeric values. It contains information related to a study on a medication called Phcebo (N-101) Immediade-release. The medication is in the form of fevetiracetam tablets and the study included 150 participants who took a dosage of 3000mg/day. The table/chart includes different percentages ranging from 0% to 39.4%. Lastly, there is a note stating that the medication was statistically significant when compared to a placebo.*

FDA Label Image

Fig4.jpg (Fig4)

The text provides a table of percentages, followed by a line that includes the name of a drug, Levetiracetam tablets, and a statement discussing significant results of a study comparing it to a placebo. Without additional context, it is difficult to determine the specific use or indications for Levetiracetam tablets.*

FDA Label Image

Levetiracetamxr-01 (Levetiracetam Xr 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.